‘Underwhelming’ trials for long Covid treatments; Wegovy’s heart study raises vital question about weight loss

A report from the U.K.'s Health Security Agency suggested the growing pool of non-immune adults could fuel future measles outbreaks.

August 9, 2023 Check out STAT+

Sponsored By

Adobe 'Underwhelming': NIH trials fail to test meaningful long Covid treatments — after 2.5 years and $1 billion The NIH says it's used up most of its $1.15 billion of long Covid funding and more money is not forthcoming, per new budget details. By Betsy Ladyzhets STAT+ | Wegovy's successful heart trial raises a vital question about weight loss Researchers say the positive results don't prove that popular new obesity treatments improve heart health solely through weight loss. By Elaine Chen and Damian Garde STAT+ | 'No data more personal': Patients, digital health players weigh in on the FTC's data privacy plan The FTC is arming itself for even more aggressive enforcement of health data privacy related to apps, telehealth websites, and more. By Katie Palmer Courtesy Pardis Sabeti Meet the scientists trying to stop the next global pandemic from starting in Africa Sentinel takes a bottom-up approach using low-cost diagnostics in community settings to track the spread of disease in real-time. By Simar Bajaj and Abdullahi Tsanni Study mapping how SARS-CoV-2 disrupts mitochondria suggests a cause for long Covid A new study maps how SARS-CoV-2 damages mitochondria in organs, leading to more severe disease and perhaps long Covid. By Elizabeth Cooney Nonprofit naloxone maker celebrates FDA approval by donating 200,000 doses Harm Reduction Therapeutics will donate 200,00 doses of its nasal spray to the Remedy Alliance, the affordable naloxone access group. By Lev Facher Adobe Failed clinical trials don't always spell doom for a new drug. Here's why While a failed clinical trial might be bad news, it isn't always an automatic deal killer for a new drug, as STAT's latest report explains. By Erica Goode

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Daily Recap? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2023, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser